AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...

Graphics processing units are AI chips used ... to lower-than-anticipated sales of its obesity drugs. Meanwhile, rival AbbVie's stock rose 2% after its earnings topped estimates thanks to sales ...

Graphics processing units are AI chips used in data centers ... expectations due to lower-than-anticipated sales of its ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The company’s shares closed yesterday at $201.68. Devarakonda ...

Highlights,AbbVie Inc. has seen strong stock performance, outpacing both the broader market and sector indexes.,The company reported better-than-expected Q3 earnings, driven by strong sales of ...

In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $202.46, changing hands for $203.87/share. When a stock reaches the target an ...

When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market, but that process can take a while.